On a quiet advertisement in the United Kingdom, a simple invitation to check one's body mass index and prepare for a conversation with a clinician has become the focus of a considered warning. The campaign, run by the drugmaker Eli Lilly, speaks truthfully about the unfairness of weight stigma, yet it also advances the company's interest in its treatment, tirzepatide. Writing in The BMJ, Michael Viggars and colleagues ask a patient question of public life: when those who profit from a remedy are also the ones shaping how an affliction is understood, what gets quietly set aside? Their answer is
Experts Warn Obesity Destigmatization Campaigns Could Serve Pharmaceutical Interests
Compassion and commercial interest can speak in the same voice.
Mark
Why single out a campaign that, by the authors' own account, is mostly accurate?
Mimi
Because accuracy is the point. They say almost everything it says about stigma is true, and that makes the commercial benefit harder to see and harder to criticize.
Mark
What do they actually fear happens?
Mimi
Not more prescriptions. They say that's a clear benefit for eligible patients. They fear a clinical-first framing that pulls attention from urban planning, the food environment, deprivation, and marketing.
Luke
Careful, though. That's a risk they describe, not something they show has happened. The piece is an analysis, and it doesn't present evidence that policy has shifted.
Mimi
Fair. They say resources and responsibility "may" drift, and obesity "may" be recast as personal and medical.
Mark
The ad never mentions a drug. Does that matter?
Mimi
It's central to their point. The campaign invites a BMI check and a conversation with a clinician, while the company's tirzepatide is a principal treatment.
Luke
What we don't know is whether the campaign increases prescriptions or changes anyone's policy views. Nothing here measures that.
Mark
And the regulatory ask?
Mimi
That the marketing code be tested against manufacturers' own campaigns, not just pharmacies, clinics, and influencers.
Luke
Which is a proposal from the authors, not a finding that the code currently fails.
Le Pouls
- A drugmaker's advertisement, carefully free of any mention of medicine, is drawing scrutiny from researchers at The BMJ.
- The campaign's core message that obesity is a disease and not a failure of willpower is largely accurate, which makes the concern harder to voice.
- Critics fear that a clinical-first framing could pull attention and resources away from urban planning, food environments, and deprivation.
- The authors are navigating a double position: backing the fight against stigma while guarding against commercial influence over that fight.
- Their proposal asks regulators to test marketing codes against manufacturers' own campaigns, a step that remains unresolved.
On a quiet advertisement in the United Kingdom, a simple invitation to check one's body mass index and prepare for a conversation with a clinician has become the focus of a considered warning. The campaign, run by the drugmaker Eli Lilly, speaks truthfully about the unfairness of weight stigma, yet it also advances the company's interest in its treatment, tirzepatide. Writing in The BMJ, Michael Viggars and colleagues ask a patient question of public life: when those who profit from a remedy are also the ones shaping how an affliction is understood, what gets quietly set aside? Their answer is not a rejection of compassion, but a call for the rules that govern marketing to examine the manufacturers themselves.
In the United Kingdom, an advertisement asks viewers to check their body mass index, answer a few questions, and prepare to speak with a doctor, nurse, or pharmacist. It never names a drug. Yet it belongs to Eli Lilly's "Obesity Is a Disease" campaign, and this week it became the subject of an analysis in The BMJ.
Michael Viggars and colleagues begin by agreeing with the campaign's aim. Destigmatizing obesity is right. Their unease lies in who is speaking and what that speech may shape. The campaign's messages are familiar: obesity is a complex disease, the body can resist weight loss, and people who struggle deserve compassion rather than blame. The authors find nearly all of these claims accurate.
That accuracy is the difficulty. Eli Lilly makes tirzepatide, now a leading treatment for obesity, so the framing is both scientifically defensible and commercially useful. The authors call this commercial influence in its subtlest form, arriving in the language of compassion that public health has long worked to build.
They are careful to say that the danger is not more prescriptions for patients who need them. The concern is that a clinical-first view of obesity may narrow the field of action. If the condition is seen mainly as something awaiting medical treatment, responsibility and resources may drift away from poor urban planning, the food environment, deprivation, and marketing, and prevention may be recast as a private medical matter.
The authors ask readers to hold two truths together: reducing stigma is right, and the pharmaceutical interest in leading that effort deserves caution. Their practical request is directed at regulators, who they say should test marketing codes against manufacturers' own campaigns, not only against the pharmacies, clinics, and influencers that sell or promote the drugs. Whether regulators will take up that challenge is left open.
In the UK, an advert invites you to check your body mass index, answer a few questions, and get ready for a conversation with a doctor, nurse, or pharmacist. It never mentions a drug. It is part of Eli Lilly's "Obesity Is a Disease" campaign, and this week it became the subject of an analysis in The BMJ.
The piece is by Michael Viggars and colleagues. Their argument starts from a concession: destigmatizing obesity is the right thing to do. What worries them is who is doing the talking, and what the talking may do to public conversation and national policy.
The campaign's messages are familiar to anyone who follows the field. Obesity is a complex disease, not a failure of willpower. The body can resist weight loss. People who have struggled for years deserve compassion rather than blame. The authors say almost everything the campaign claims about stigma is true.
That, in their view, is the difficulty. Eli Lilly makes tirzepatide, now a principal treatment for obesity. The framing is scientifically defensible and also commercially useful, and the authors say this overlap is exactly what makes it harder to criticize. They call it commercial determinants of health in their subtlest form, and argue that commercial influence is far less easily spotted when it arrives in the language of compassion and destigmatization that public health has spent years cultivating.
They are careful about what they are not saying. The main risk, they write, is not that more people will be prescribed weight loss drugs; for eligible patients, that is a clear benefit. The risk is that the campaign endorses a clinical-first approach to obesity, which narrows the field of action.
If obesity is understood chiefly as a disease awaiting clinical intervention, they explain, responsibility and resources may drift away from upstream causes: poor urban planning, the food environment, deprivation, and marketing. Treatment and prevention could be quietly recast as a personal, medical matter rather than a collective responsibility.
The authors say the task is to hold two positions at once: that reducing stigma is right, and that caution is warranted about the vested interest pharmaceutical companies have in leading that effort.
Their practical proposal is aimed at regulators. They say the marketing code should be tested, and its limits identified, by reference to campaigns like this one run by a manufacturer, not only in relation to the pharmacies, clinics, or influencers who sell or promote the drugs. Whether regulators take up that challenge is the question the piece leaves open.
Citations marquantes
Obesity treatment and prevention may be quietly recast as only a personal, medical matter rather than a collective responsibility.— Michael Viggars and colleagues, The BMJ
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗